Direxion S&P Biotech Bear 3X

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

XORTX Therapeutics closes US$5 million follow-on offering at US$1.88/share

XRTX

LABD

LABU

SBIO

XORTX Therapeutics has completed a US$5 million public offering at US$1.88 per share, issuing 183,577 common shares and 2,475,997 pre-funded warrants. The net proceeds will be used for working capital, corporate purposes, and investor relations. E.F. Hutton received a US$200,000 commission, and US$2.5 million will be allocated to IR Agency LLC for marketing services.

PUBT

XORTX Therapeutics

VanEck Biotech ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

00945

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

Guardant Health

MANULIFE-S

Manulife Financial

Ark Genomic Revolution ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

China Merchants CSI Biotechnology Theme ETF

Manulife Singapore to offer multi-cancer blood test starting May

IVVD

Invivyd (NASDAQ:IVVD) reported a quarterly EPS of ($0.13), missing estimates by ($0.05), with revenue of $13.74 million below the expected $18.04 million. The company has a negative return on equity of 48.65% and a net margin of 98.25%. Despite challenges, Invivyd's VYD2311 study is progressing well, and PEMGARDA revenue grew 22% year-over-year. Shares fell 21.1% to $1.16, with significant insider selling noted. Institutional investors have increased their stakes, with 70.36% of shares held by hedge funds.

Market Beat

Invivyd

VG Health

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Health Care Select Sector SPDR

Invivyd (NASDAQ:IVVD) Issues Earnings Results

GRI Bio reported promising Phase 2a data for its IPF candidate GRI-0621, showing significant improvements in clinical symptoms and safety compared to standard antifibrotics. The company ended Q1 2026 with $11 million in cash and narrowed its net loss to $2 million. Analysts rate GRI stock as a Buy with a $10 target, though concerns about financial performance and technical indicators persist. GRI Bio focuses on therapies for inflammatory and autoimmune diseases, with a pipeline aimed at immune modulation.

Tip Ranks

GRI Bio

GRI Bio Highlights Promising Phase 2a IPF Data, Outlook

NNNN

Anbio Biotechnology's shareholders approved several resolutions at an extraordinary general meeting on May 15, 2026. Key decisions included a reduction in par value of shares, an increase in authorized share capital to USD 3,000, and endorsement of new Class B ordinary shares with enhanced voting rights. Share consolidation authority was also granted, although no specific consolidations were confirmed.

Anbio Biotechnology

SPDR S&P Health Equip

iShares US Medical Devices

Anbio Biotechnology shareholders approve restated charter at extraordinary general meeting

RGNX

Bank of America has lowered its price target for REGENXBIO (NASDAQ:RGNX) from $25.00 to $14.00 while maintaining a 'buy' rating. The new target suggests a potential upside of 139.93%. Other analysts have also adjusted their ratings, with a consensus price target of $23.91. REGENXBIO's stock is currently trading at $5.84, down 6.5%, with a market cap of $301.20 million. The company reported a loss of $1.72 EPS in its last earnings report, missing expectations significantly.

Regenxbio

Bank of America

Morgan Stanley

State Street

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

State Street® US Equity Premium Inc ETF

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

BCDA

BioCardia will participate in a virtual fireside chat at Alliance Global Partners’ Healthcare Company Showcase on May 20, 2026, at 11:40 a.m. ET.

BioCardia

BioCardia joins A.G.P. Healthcare Company Showcase fireside chat

ARWR

Arrowhead Pharmaceuticals Director Hongbo Lu sold 2,970 shares at $76.88 each, totaling $228,333.60, reducing his stake by 5.40%. Post-sale, he holds 52,012 shares valued at approximately $3.99 million. The transaction was disclosed to the SEC and executed under a Rule 10b5-1 plan. The stock recently traded up 2.3% to $79.69, with a market cap of $11.23 billion and a negative earnings per share of -$0.93 for the last quarter.

ArrowHead Pharma

Bank of Nova Scottia

JPMorgan Chase

ROYAL BANK OF CANADA

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock

MEDP

IDNA

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

prnewswire

Medpace

iShares US Healthcare Providers

iShares Genomics Immunology and Healthcare ETF

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

LEGN

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Despite this, the stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets, with RBC Capital raising its target from $62 to $64, Morgan Stanley lowering it from $49 to $48, and TD Cowen increasing it from $21 to $29. CEO Ying Huang emphasized the company's growth and path toward sustainable profitability.

benzinga_article

Legend Biotech

Toronto Dominion Bank

Shutterstock

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

SANA

Wedbush analyst Martin Fan has maintained a Buy rating on Sana Biotechnology (SANA) with a price target of $7.00. Fan, a 5-star analyst with a 69.44% success rate, focuses on the Healthcare sector. Additionally, Bank of America Securities also reiterated a Buy rating on the stock with the same price target of $7.00.

Sana Biotechnology

Nektar Therap

Oruka Therapeutics

Sana Biotechnology (SANA) Receives a Buy from Wedbush

Direxion S&P Biotech Bear 3X(LABD.US)